Based on our data FAK-inhibition alone or in combination with 2nd generation TRAIL-receptor agonists may be recommended for treatment of primary or therapy resistant relapsed MM metastasis irrespective of the intrinsic mutation status. This evidence concerns the gene PTK2 and Miyoshi myopathy.